breast cancer

News

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.

News

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

News

Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan.

News

A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.

News

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours

Oncology

Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.